Neurogastrx, Inc.

WOBURN, MA · Founded 2017 · CIK 0001870700 · Biotech · Private

Biopharmaceutical therapeutics for gastrointestinal diseases

neurogastrx.com →
Grants
—
No SBIR or STTR on record
Sector median: 1
Raised
$80M
2 Form D · Jul 2021
63 months since last filing
Contracts
—
No federal contracts on record
Patents
26
7 granted · 19 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Private capital raisedForm D · SEC$20,000,000
Private capital raisedForm D · SEC$60,000,002
Form D · SEC

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
1786SmartLife, Inc.—$225K
1787Evofem Biosciences, Inc.—$86M
1788AGILE THERAPEUTICS INC—$81M
1789Neurogastrx, Inc.—$80M
1790Azafaros——
1791Faknostics, LLC——
1792Green Growth Brands Inc.—$17M

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Founders & Team

From Form D filings · 9 related persons
  • DAVID ALLISONDirector
  • CYRIL DE COLLEDirector · Executive Officer
  • JAMES DETOREExecutive Officer
  • KEVIN KOCHDirector
  • JAMES O'MARADirector · Executive Officer
  • PAUL ROGERSExecutive Officer
  • AARON ROYSTONDirector
  • KLAUS VEITINGERDirector
  • KLAUS VETTINGERDirector

Patents

USPTO · 7 granted of 26

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.